Interest surrounding glucagon-like peptide 1 agonists (GLP-1), a class of type 2 diabetes drugs that help blood sugar management and may lead to weight loss, continues to grow. With more medications ...

Novo Nordisk NVO received FDA approval for a regulatory application seeking the label expansion of its oral GLP-1 drug, Rybelsus (semaglutide), to include cardiovascular (CV) risk reduction in adults ...

Semaglutide is a prescription medication. Injectable forms of the drug are available under the brand names Ozempic and Wegovy. The pill form of semaglutide is available as the brand-name drug Rybelsus ...

The FDA approved Novo Nordisk’s oral semaglutide (Rybelsus) for cardiovascular (CV) risk reduction in adults with type 2 diabetes (T2D) who are at high CV risk, whether or not they’ve had a prior CV ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved oral semaglutide for primary and secondary prevention of CV events in high-risk adults with ...

Rybelsus is now also indicated for cardiovascular risk reduction in adults with Type 2 diabetes who are at high risk, including those who have not had a prior CV event. This new indication makes ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...